Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells

HIV Medicine

Volumn 4, Issue 4, 2003, Pages 338-345

  Dupuis, Maria Luisa ^a   Flego, M ^a   Molinari, A ^a   Cianfriglia, M ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

CEMrev cells; HIV 1; Multidrug resistance; P glycoprotein; Saquinavir; Tumours

Indexed keywords

CD4 ANTIGEN; DILUENT; GLYCOPROTEIN P; INDINAVIR; ISOPROTEIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS GLYCOPROTEIN;

ARTICLE; BIOCHEMISTRY; CELL CULTURE; CELL TRANSFER; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; DRUG EXPOSURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCHEMISTRY; IN VITRO STUDY; LYMPHOBLASTOID CELL LINE; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN TRANSPORT; REVERTANT; T LYMPHOCYTE; TARGET CELL;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; INDINAVIR; P-GLYCOPROTEIN; PHENOTYPE; RITONAVIR; SAQUINAVIR;

EID: 0142217480     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2003.00169.x     Document Type: Article

References (41)

1. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983; 221: 1285-1288.
2. Ueda K, Cornwell MM, Gottesman MM et al. The mdr1 gene, responsible for multidrug resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 1986; 141: 956-962.
3. Germann UA, Pastan I, Gottesman MM. P-glycoproteins: mediators of multidrug resistance. Semin Cell Biol 1993; 4: 63-76.
4. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989; 58: 137-171.
5. Schinkel AH, Borst P. Multidrug resistance mediated by P-glycoproteins. Semin Cancer Biol 1991; 2: 213-226.
6. Kim RB, Fromm MF, Wandel C et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289-294.
7. Lee CG, Gottesman MM, Cardarelli CO et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37: 3594-3601.
8. Jones K, Hoggard PG, Sales SD, Khoo S, Davey R, Back DJ. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 2001; 15: 675-681.
9. Washington CB, Duran CE, Man MC, Sikic BI, Blaschke TF. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19: 203-209.
10. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80: 2735-2739.
11. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83: 2451-2458.
12. Ludescher C, Pall G, Irschick EU, Gastl G. Differential activity of P-glycoprotein in normal blood subsets. Br J Haematol 1998; 101: 722-727.
13. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-7738.
14. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990; 38: 1277-1287.
15. Hoetelmans RM Sanctuary sites in HIV-1 infection. Antivir Ther 1998; 3 (Suppl. 4): 13-17.
16. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000; 14: 237-242.
17. van Tellingen O. The importance of drug transporting P-glycoproteins in toxicology. Toxicol Lett 2000; 120: 31-41.
18. Perloff MD, von Moltke LL, Marchand JE, Greenblatt DJ. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci 2001; 90: 1829-1837.
19. Profit L, Eagling VA, Back DJ, Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 1999; 13: 1623-1627.
20. Karp JE, Groopman JE, Broder S. Cancer in AIDS. In: de Vita VT, Helmann S Jr, Rosenberg S, eds. Cancer Principles and Practice of Oncology, 4th edn. Philadelphia: JB Lippincott Co., 1993: 2093-2110.
21. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-124.
22. Bosch I, Croop J. P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta 1996; 1288: F37-F54.
23. Ratner L, Lee J, Tang S et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001; 19: 2171-2178.
24. Schinkel AH. P-glycoprotein a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999; 36: 179-194.
25. Beck WT, Mueller TJ, Tanzer LR. Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res 1979; 39: 2070-2076.
26. Cianfriglia M, Cenciarelli C, Tombesi M et al. Murine monoclonal antibody recognizing a 90-kDa cell-surface determinant selectively lost by multi-drug-resistant variants of CEM cells. Int J Cancer 1990; 45: 95-103.
27. Cianfriglia M, Willingham MC, Tombesi M, Scagliotti GV, Frasca G, Chersi A. P-glycoprotein epitope mapping. I. Identification of a linear human-specific epitope in the fourth loop of the P-glycoprotein extracellular domain by MM4.17 murine monoclonal antibody to human multi-drug-resistant cells. Int J Cancer 1994; 56: 153-160.
28. Trambas C, Wang Z, Cianfriglia M, Woods G. Evidence that natural killer cells express mini P-glycoproteins but not classic 170 kDa P-glycoprotein. Br J Haematol 2001; 114: 177-184.
29. Georges E, Bradley G, Gariepy J, Ling V. Detection of P-glycoprotein isoforms by gene specific monoclonal antibodies. Proc Natl Acad Sci USA 1990; 87: 152-156.
30. Puddu P, Fais S, Luciani F et al. Interferon-gamma up-regulates expression and activity of P-glycoprotein in human peripheral blood monocyte-derived macrophages. Lab Invest 1999; 79: 1299-1309.
31. Luciani F, Molinari A, Lozupone F, Calcabrini A et al. P-glycoprotein-actin association through ERM family proteins: a role in P-glycoprotein function in human cells of lymphoid origin. Blood 2002; 99: 641-648.
32. Rao VV, Anthony DC, Piwnica-Worms D. MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase. Cancer Res 1994; 54: 1536-1541.
33. Thévenod F, Hildebrandt JP, Striessnig J, de Jonge HR, Schulz I. Chloride and potassium conductances of mouse pancreatic zymogen granules are inversely regulated by an approximately 80-kDa mdr1a gene product. J Biol Chem 1996; 271: 3300-3305.
34. 2+-dependent exocytosis in pancreatic cells is mediated by a 65-kDa mdr-like P-glycoprotein. Proc Natl Acad Sci USA 1999; 96: 5539-5544.
35. + T-lymphoblastoid CEM cell line. Chemotherapy 2003; 49: 8-16.
36. Mechetner EB, Schott B, Morse BS et al. P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity. Proc Natl Acad Sci USA 1997; 94: 12908-12913.
37. Nagy H, Goda K, Arceci R, Cianfriglia M, Mechetner E, Szabo G Jr. P-glycoprotein conformational changes detected by antibody competition. Eur J Biochem 2001; 268: 2416-2420.
38. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
39. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549.
40. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev Cancer 2002; 2: 48-58.
41. Lucia MB, Rutella S, Leone G, Larocca LM, Vella S, Cauda R. In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin. J Acquir Immune Defic Syndr 2002; 30: 369-378.